DNA-Topoisomerase I, a new target for the treatment of neuroblastoma
- 1 October 1997
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (12), 2011-2015
- https://doi.org/10.1016/s0959-8049(97)00296-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsBritish Journal of Cancer, 1996
- Drug Evaluation: Oncologic, Endocrine & Metabolic: Irinotecan (CPT-11): Current status and perspectivesExpert Opinion on Investigational Drugs, 1996
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI Journal of the National Cancer Institute, 1994
- Effects of CPT‐11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno‐transplanted neuroblastomaMedical and Pediatric Oncology, 1994
- Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1994
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989
- Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835International Journal of Cancer, 1989
- Preclinical phase II studies in human tumor lines: A European multicenter studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Proposal for the Application of Xenografts in Screening for New Anticancer Agents and in Selecting Tumor Types for Phase II Clinical TrialsPublished by Springer Nature ,1988